Press release
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging
About this update from Insmed Incorporated
[{"type":"text","content":"—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary Arterial Hypertension (PAH), and Pulmonary Vasodilation Data in Rat Models—BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin from January 28 – February 1, 2026.Presentations will feature the Phase 3 PALM-PAH study design and an encore presentation of the topline results from the Phase 2b study of TPIP in pulmonary arterial hypertension (PAH). Additionally, a new Functional Respiratory Imaging analysis from the Phase 2b PAH study, as well as data evaluating the pulmonary vasodilatory effect of TPIP in rat models will be presented.\"We are pleased that TPIP will have a significant presence at this year's PVRI 2026 congress, reflecting the growing body of evidence supporting its potential to become the prostanoid of choice,\" said Martina Flammer, M.D., MBA, Chief Medical Officer, Insmed. \"Collectively, these Phase 2b clinical, advanced imaging, and translational preclinical data provide a strong foundation as we initiate multiple Phase 3 programs, including the PALM-PAH study, with the goal of improving outcomes for patients.\"Presentations:Presentation Details, Moderated Poster Discussion – Robinson, Friday, January 30, 2026, 15:10 – 16:15, Robinson Suite, Poster Board: 41Lead Author and Presenter: Tam NguyenTitle: Pulmonary Vasodilation with TPIP in Rat Isolated Perfused LungsPresentation Details, Moderated Poster Discussion – Higgins, Saturday, January 31, 2026, 09:55 - 11:00, Higgins Suite, Poster Board: 7Lead Author: Ekkehard Grünig, Presenter: Raymond BenzaTitle: Study Design of a Phase 3 Trial of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension (PAH)Presentation Details, Moderated Poster Discussion – Higgins, Saturday, Jan 31, 2026, 09:55 - 11:00, Higgins Suite, Poster Board: 8 Lead Author and Presenter: Ioan...